retatrutide 3 week results VisualAbstract: reduces body weight by 17.5% in patients with obesity First Retatrutide phase 3 data,
Description
10.1161/01.CIR.0000120505.91348.58 207

Synergy with GLP-1 : When combined, GIP and GLP-1 amplify weight loss, insulin sensitivity, and glucose control better than GLP-1 alone

If you choose to stop the injections, maintaining a healthy lifestyle remains essential to preserving your results

Understanding Triple Agonist Weight Loss Medications Triple agonist medications represent the next generation of weight loss treatments
Potential risks associated with their prolonged use may include gastrointestinal disturbances, including nausea, vomiting, diarrhea, and constipation [21,27,28,29]

For researchers, this opens up incredible avenues of study, but it also means you're working with a compound of immense potency
